Texas Uni’s sovereign immunity fail went as expected
The result of the sovereign immunity bid mirrored previous cases but we did learn something about the opinions of Justices on the issue, says Gary Frischling of Milbank.
Second medical use: a regulatory perspective
Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.
The importance of Minerva Surgical v Hologic
A decision by the Supreme Court over the assignor estoppel doctrine could have far-reaching implications for patent law, argue Jeffrey D Morton, Zachary Schroeder and Ryan D Ricks of Snell & Wilmer.
What 2020 means for the life sciences
Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.
Pricing, patents and the PMPRB in Canada
Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.
The doctrine of equivalents in the medtech arena
The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.
The plausibility battleground at the EPO
Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.
A stricter interpretation: the EPO and antibodies
Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.
COVID-19: Protection of IP for AI tools
As AI becomes a crucial weapon in the battle against the global pandemic, companies in the field need to ensure that their valuable IP is protected, as Mao Xiao Hong and Danny Yap of IPOS International explain.
Why Santen ends Neurim-style SPCs
In a boost for generic pharma companies, a U-turn by the EU’s highest court removed protection for repurposed active substances, as Robert Stephen and Gareth Morgan of CMS Cameron McKenna Nabarro Olswang explain.
